Ambrisentan Structural Formula (Image 01)
Ambrisentan Tablet, Film Coated
Product Images NDC 0378-4270
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ambrisentan (NDC 0378-4270). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2: Effects Of Other Drugs On Ambrisentan Pharmacokinetics (Image 02)
This appears to be a chart or table with information regarding interacting drugs and their PK values, Cmax and Auc. It also includes recommendations for dose adjustment and fold change percentages relative to ambrisentan alone. Some of the drugs listed include cyelosporine, mycophenolate mofetil, ketoconazole, omeprazole, rifampin, ritonavir, sildenafil, tacrolimus, and warfarin. There is a note regarding the results of co-administering rifampin and a mention of a population pharmacokinetic analysis for omeprazole in PAH patients.*
Figure 3: Effects Of Ambrisentan On Other Drugs (Image 03)
This is a table describing the interactions of various drugs with each other. It provides information about peak concentration (Cmax) and the area under the curve (AUC) for each drug when taken alone or in combination. It also provides recommendations for dose adjustments, if necessary. There is also a note about the active metabolite of mycophenolate mofetil.*
Figure 4 Mean Change In 6-minute Walk Distance (aries-1 And Aries-2) (Image 04)
The text is a report on the mean change from baseline in 6-minute walk distance for the placebo and ambrisentan tablet groups in week 12. The values are expressed as the mean with the standard error of the mean. The report is related to a study or experiment named ARIES-1.*
Figure 5 Time To Clinical Worsening (aries-1 And Aries-2) (Image 05)
This text appears to be a figure caption from a clinical trial that compares the time to clinical worsening between patients taking ambrisentan tablets and placebo. The trial was divided into two parts: ARIES-1 and ARIES-2. The p-values shown in the figure are the log-rank comparisons of ambrisentan tablets to placebo, stratified by patients with idiopathic or heritable pulmonary arterial hypertension (PAH) and those with non-idiopathic, non-heritable PAH.*
Acceptable Birth Control Options (Image 06)
Ambrisentan Tablets 5 mg Bottle Label (Image 07)
This is a medication container label for Ambrisentan 5mg coated tablets. The label states the dosage, administration instructions, storage suggestions, and manufacturing information. It also reminds to keep the medication out of reach of children and to dispense the medication guide with each prescription. The medication is manufactured for Hylan Pharmaceuticals Inc. located in Morgantown, USA.*
Ambrisentan Tablets 10 mg Bottle Label (Image 08)
This is a medication guide for Ambrisentan tablets. The usual dosage information is included in an accompanying document. The tablets should not be split, crushed, or chewed and should only be dispensed in their original container. The manufacturer is Hylan Pharmaceuticals Inc. and the medication is to be taken by patients as per their individual prescription. There is also mention of a USP controlled room temperature. There is no information available regarding the specific condition being treated or the purpose of the medication.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
